Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Thoracic 8Other hematologic neoplasm 8Breast 8Gastrointestinal 7Other solid neoplasm 6Gynecologic 5CNS 4Lymphoid 3Head & Neck 3Sarcoma 2Plasma cell 2Genitourinary 2Tumor-Agnostic 1NET 1Myeloid 1Endocrine 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interleukin-2 × NET × Clear all
NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
51 enrolled
EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡